KLRS
Kalaris Therapeutics, Inc.
3.20$
+1.3%
vs. previous close
Closing price · As of: Sep 18, 2026
Statements
Cash Flow
Kalaris Therapeutics, Inc. (KLRS) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (2025), "Operating Cash Flow" came in at -43 million USD. Tick rows to compare them in a chart.
All figures in millions of USD.
Tick rows to compare them in a chart (up to 4)
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| 1.9 | -20 | -61 | -106 | -9.8 | -14 | -68 | -43 | |
| – | 0.0 | 0.1 | 1.1 | – | – | 0.0 | 0.0 | |
| – | – | – | – | 0.3 | 0.1 | 0.9 | 1.9 | |
| 3.4 | 1.4 | -1.0 | 19 | 3.4 | -1.1 | -25 | 3.4 | |
| 0.0 | 0.3 | 0.2 | 0.0 | 0.0 | 0.0 | 0.0 | 0.2 | |
| – | -65 | -169 | 186 | – | – | 95 | -20 | |
| -10 | – | – | – | – | – | – | – | |
| – | – | – | – | 4.3 | 6.0 | 20 | 7.5 | |
| 23 | 121 | 292 | 0.2 | 13 | 14 | 0.0 | 160 | |
| 25 | 36 | 62 | 79 | 3.0 | 0.1 | 28 | -20 | |
| 1.9 | -20 | -61 | -106 | -9.8 | -14 | -68 | -43 |
Data as of: September 18, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.